Skip to content

Study · Not a test of the peptide alone · 2025

2 results

A multifunctional mitochondria-protective gene delivery platform promote intervertebral disc regeneration.

Wang Y, Deng M, Wu Y, Zheng C, Zhang F, Guo C, Zhang B, Hu C, Kong Q, Wang Y

Biomaterials27 Dec 2024Cited by 11 (Europe PMC)

PMID39742837 (opens in a new tab)DOI10.1016/j.biomaterials.2024.123067 (opens in a new tab)PepBankPUB-39742837
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In an in vivo model of intervertebral disc degeneration, a hydrogel platform delivering miR-21 inhibitor and ss‑31 gave synergistic extracellular matrix regeneration and anti-inflammatory effects.

    In plain wordsIn an animal model, a gel delivering a miR-21 inhibitor and ss‑31 helped disc tissue regrow and lowered inflammation.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseExtracellular matrix regeneration and anti-inflammatory effect in intervertebral disc degeneration
    Study

    n: not reported in source

    In vivo model of intervertebral disc degeneration
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Synergistic ECM regeneration and anti-inflammatory effects were sufficient to provide therapeutic benefits in an in vivo model of IDD.
    1 context sentence
    Summary · context
    This engineered platform was designed for the sustained on-demand delivery of both miR-21 inhibitor and ss-31 (mitochondrial-targeted peptide) constructs to the NP.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  2. 02LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism

    In degenerated nucleus pulposus cells, a hydrogel platform delivering miR-21 inhibitor and ss‑31 targeted damaged mitochondria and reduced inflammatory activity by suppressing the mitochondrial ROS-NLRP3-IL-1β/Caspase1 pathway.

    In plain wordsIn lab tests, a gel delivering a miR-21 inhibitor and ss‑31 lowered inflammation signals in disc cells.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseInflammatory activity via mtROS-NLRP3-IL-1β/Caspase1 pathway
    Study

    n: not reported in source

    Degenerated nucleus pulposus cells
    Outcome group
    Inflammation markers · Musculoskeletal

    Source sentences

    Summary
    At the same time, ss-31 was able to target damaged mitochondria and alleviate inflammatory activity via the suppression of mitochondrial ROS-NLRP3-IL-1β/Caspase1 pathway activity.
    1 context sentence
    Summary · context
    This engineered platform was designed for the sustained on-demand delivery of both miR-21 inhibitor and ss-31 (mitochondrial-targeted peptide) constructs to the NP.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.